Eiger BioPharmaceuticals PEG Ratio

Eiger BioPharmaceuticals (EIGRQ) currently reports a PEG ratio of 0.36. That is below the Healthcare sector average of 2.56. Use the charts on this page to explore Eiger BioPharmaceuticals's PEG ratio history and peer comparisons.

Eiger BioPharmaceuticals's PEG ratio of 0.36 is lower than the Healthcare sector average of 2.56. That is roughly 85.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Eiger BioPharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 0.36, EIGRQ can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of 0.36, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 2.56. From there, open related valuation or income-statement pages for Eiger BioPharmaceuticals, and consider following EIGRQ for alerts when major investors trade the stock.

Eiger BioPharmaceuticals is classified in the Healthcare sector. On PEG ratio, it currently shows 0.36 versus a sector average near 2.56. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EIGRQ with unrelated industries.